Tyrer-Cuzick Score: Definition, Interpretation, and Risk-Based Management
The Tyrer-Cuzick (TC) model is a validated breast cancer risk assessment tool that calculates 10-year and lifetime absolute risk of developing breast cancer by incorporating detailed family history (including second-degree relatives and age at diagnosis), personal factors, breast density, and reproductive history—making it superior to simpler models when significant family history is present. 1
What the Tyrer-Cuzick Score Measures
The TC model provides:
- 10-year absolute risk of developing breast cancer
- Lifetime (residual) absolute risk of developing breast cancer
- Version 8 can also estimate 5-year risk 1
The model incorporates multiple risk factors including:
- Detailed family history (first- and second-degree relatives, age at cancer diagnosis)
- Personal history of atypical hyperplasia (AH) or lobular carcinoma in situ (LCIS)
- Mammographic breast density
- Age, reproductive history, and hormonal factors
- Body mass index 1, 2
Risk Stratification Thresholds
High-Risk Definition
Women are considered high-risk and should be offered endocrine risk reduction therapy when they have:
For specific age groups requiring endocrine prevention:
- Age 40-44 years: ≥4 times the population risk
- Age 45-69 years: ≥2 times the population risk
- Age 60-70 years: ≥1.5 times the population risk 1
Intermediate Risk
Women with 10-year risk between 3-5% or who don't meet high-risk criteria but have elevated risk factors warrant closer surveillance and individualized discussion.
Average Risk
10-year risk <3% and lifetime risk <20% without high-risk lesions.
Management Recommendations by Risk Category
High-Risk Management (10-year risk ≥5% or lifetime risk ≥20%)
Endocrine Risk Reduction Therapy (for postmenopausal women ≥35 years):
First-line options 1:
- Anastrozole 1 mg/day orally for 5 years (preferred for most)
- Tamoxifen 20 mg/day for 5 years (if premenopausal or contraindications to aromatase inhibitors)
- Raloxifene 60 mg/day for 5 years (postmenopausal only)
- Exemestane 25 mg/day for 5 years
Before initiating anastrozole 1:
- Evaluate baseline fracture risk and measure bone mineral density
- Severe osteoporosis (T-score <-4 or >2 vertebral fractures) is a relative contraindication
- Consider bone-protective agents (bisphosphonates, RANKL inhibitors) if moderate bone loss
- Counsel on joint stiffness, arthralgias, vasomotor symptoms, hypertension, dry eyes, vaginal dryness
Enhanced screening 3:
- Annual screening mammography
- Supplemental breast MRI for lifetime risk ≥20%
- Consider contrast-enhanced mammography or molecular breast imaging if MRI contraindicated
Genetic counseling referral 3, 5:
- 66-75% of high-risk patients offered genetics consultation participate
- 50% complete genetic testing when offered
Special Populations Requiring Endocrine Therapy Discussion
All women ≥35 years with atypical hyperplasia or LCIS should be offered endocrine therapy regardless of calculated TC score, as these lesions confer 4-10 fold increased risk (5-year risk 3-5%, 10-year risk 5-10%) 1. This applies equally to women of African descent, whose TC scores may underestimate risk.
Intermediate and Average Risk Management
Women with 10-year risk <5% and no high-risk lesions:
- Standard screening mammography per age-appropriate guidelines
- Periodic risk reassessment as risk increases with age 2
- Lifestyle modification counseling
Clinical Implementation Considerations
When to Use TC vs. Other Models
- Significant family history present (≥2 first- or second-degree relatives with breast cancer)
- Age at cancer diagnosis in relatives is known
- More detailed risk assessment needed beyond simple Gail model
The TC model is more appropriate than the Gail model when family history includes age at onset or second-degree relatives 1.
Accuracy and Validation
The TC model demonstrates excellent long-term calibration:
- Observed/Expected ratio: 0.98 (95% CI 0.94-1.02) with density included 6
- Maintains accuracy for 10+ years of follow-up 6
- Hazard ratio for highest risk decile vs. middle 80%: 2.55 (95% CI 2.33-2.80) when density included 6
Important Caveats
Mammographic density is a major driver of TC scores: In populations with high breast density prevalence (>75%), TC may classify 13-24% more women as high-risk compared to Gail model 4
TC predicts BRCA1/2 mutations better than non-BRCA pathogenic variants: Higher TC scores are associated with BRCA1/2 mutations but not reliably with CHEK2, BARD1, or other non-BRCA pathogenic variants 7. Use NCCN or ASBrS guidelines for genetic testing decisions, not TC alone.
Most women identified as high-risk will never develop breast cancer: Risk models have modest discriminatory accuracy at the individual level despite good population-level calibration 2
Risk assessment should begin at age 25 years per national recommendations, though implementation in routine practice remains inconsistent 5